Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer

Anticancer Research

Volumn 33, Issue 4, 2013, Pages 1717-1720

  Naumann, David ^a   Rusius, Victoria ^b   Margiotta, Chiara ^c   Nevill, Alan ^d   Carmichael, Amtul ^b   Rea, Daniel ^c   Sintler, Martin ^a  

^a SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST   (United Kingdom)

^b DUDLEY GROUP OF HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

Author keywords

Breast cancer; Cardiotoxicity; HER2; Trastuzumab

Indexed keywords

ANTHRACYCLINE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; COHORT ANALYSIS; DRUG EXPOSURE; DRUG INDICATION; FEMALE; GROUPS BY AGE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIMARY TUMOR; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; COHORT STUDIES; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HEART DISEASES; HUMANS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RISK FACTORS;

EID: 84876774590     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Pegram M and Liao J: Trastuzumab treatment in multiple lines: Current data and future directions. Clin Breast Cancer 12(1): 10-18, 2012.
2. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez Rovira P, Piccart-Gebhart MJ, Hera study team: Two-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369(9555): 29-36, 2007. (Pubitemid 46039831)
3. Zeglinski M, Ludke A, Jassal DS and Singal PK: Trastuzumab-induced cardiac dysfunction: A 'dual-hit'. Exp Clin Cardiol 16(3): 70-74, 2011.
4. Albini A, Cesana E, Donatelli F, Cammarota R, Bucci EO, Baravelli M, Anza C and Noonan DM: Cardio-oncology in targeting the HER receptor family: The puzzle of different cardiotoxicities of HER2 inhibitors. Future Cardiol 7(5): 693-704, 2011.
5. Keefe DL: Trastuzumab-associated cardiotoxicity. Cancer 95(7): 1592-1600, 2002.
6. Perez EA and Rodeheffer R: Clinical cardiac tolerability of trastuzumab. J Clin Oncol 22(2): 322-329, 2004. (Pubitemid 41095098)
7. Ewer SM and Ewer MS: Cardiotoxicity profile of trastuzumab. Drug Saf 31(6): 459-467, 2008. (Pubitemid 351695459)
8. + breast cancer. Adv Ther 26(Suppl 1): S9-17, 2009.
9. Harnett A, Smallwood J, Titshall V and Champion A: Diagnosis and treatment of early breast cancer, including locally advanced disease - summary of NICE guidance. BMJ 338: b438, 2009.
10. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20(5): 1215-1221, 2002. (Pubitemid 34177427)
11. Tarantini L, Cioffi G, Gori S, Tuccia F, Boccardi L, Bovelli D, Lestuzzi C, Maurea N, Oliva S, Russo G, Faggiano P, Italian Cardio-Oncologic Network: Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail 18(2): 113-119, 2012.
12. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW and Yancy CW: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46(6): e1-82, 2005.
13. Piccirillo JF, Tierney RM, Costas I, Grove L and Spitznagel EL Jr.: Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291(20): 2441-2447, 2004. (Pubitemid 38669187)
14. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkio S, Flander M, Helle L, Ingalsuo S, Johansson K, Jaaskelainen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J, FinHer Study Investigators: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354(8): 809-820, 2006. (Pubitemid 43290919)
15. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J, Breast Cancer International Research Group: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14): 1273-1283, 2011.
16. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN and Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16): 1673-1684, 2005. (Pubitemid 41464706)
17. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD, Herceptin Adjuvant Trial Study Team: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16): 1659-1672, 2005. (Pubitemid 41464705)
18. Rayson D, Richel D, Chia S, Jackisch C, van der Vegt S and Suter T: Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: Current experience and future strategies. Ann Oncol 19(9): 1530-1539, 2008.
19. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V and Lenihan DJ: Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 23(31): 7820-7826, 2005. (Pubitemid 46657379)
20. Mackey JR, Clemons M, Cote MA, Delgado D, Dent S, Paterson A, Provencher L, Sawyer MB and Verma S: Cardiac management during adjuvant trastuzumab therapy: Recommendations of the Canadian Trastuzumab Working Group. Curr Oncol 15(1): 24-35, 2008.
21. + early breast cancer using cardiac MRI. BMC Cancer 11: 318, 2011.